DA
VRDN icon

Doliver Advisors’s Viridian Therapeutics VRDN Stock Holding History

Doliver Advisors’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$551K Buy
+30,000
New +$483K 0.12% 115

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Doliver Advisors's VRDN Position: Q2 2026 in Review

Doliver Advisors opened a new position in Viridian Therapeutics (VRDN) in Q2 2026: 30,000 shares worth $551K. The stake represents 0.12% of the portfolio and ranks #115 among its holdings.

214 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • Doliver Advisors held 30,000 shares of Viridian Therapeutics worth $551K as of Q2 2026.
  • Viridian Therapeutics was a new Doliver Advisors position in Q2 2026.
  • Viridian Therapeutics made up 0.12% of Doliver Advisors's portfolio in Q2 2026, its #115 holding.
  • 214 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Doliver Advisors's 13F filing for Q2 2026, filed 10 Jul 2026.